3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent push into cancer treatment, best-in-class operating metrics, and cheap valuation make it a stock worth owning.
Make no mistake -- Gilead Sciences' decision to leapfrog to the forefront of oncology research by acquiring Kite Pharma is a big reason why this company's stock should be in your portfolio.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Aktie
297,40 €
-0,25 %
Mit 28 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ist Amgen Inc. einer der Lieblinge unserere Community.
Das Kursziel von 304 € für Amgen Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 297.4 € hin.
